IGF-DES (IGF-1 DES[1-3])Growth Factor Analog PeptideSafety Rating 4/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 1mg
Overview
About IGF-DES
Mechanism of action
Truncated IGF-1 lacking the first 3 amino acids; does NOT bind IGF binding proteins (IGFBPs) — results in 10x greater potency at the receptor vs. standard IGF-1 LR3; direct, unhindered IGF-1 receptor activation at injection site.
Safety profile
Hypoglycemia risk, localized muscle swelling, potential for disproportionate site growth, insulin resistance, water retention. Similar risk profile to IGF-1 LR3. · More potent than IGF-1; hypoglycemia proven; tumor promotion concern; mechanistic risk basis
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops IGF-DES below your target.
Related pages
More on IGF-DES
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Des(1-3)IGF-I lacks the N-terminal Gly-Pro-Glu tripeptide and has been isolated from bovine colostrum, human brain tissue, and porcine uterus as a natural post-translational processing product; it demonstrates approximately 10-fold greater cellular potency than full-length IGF-I primarily because it binds negligibly to IGF-binding proteins (IGFBPs), leaving more free peptide available at the receptor.
- A 1989 Biochemical Journal study established the core mechanism: IGFBP preparations that potently inhibited IGF-1 and IGF-2 bioactivity had no inhibitory effect on des-(1-3)-IGF-I, directly demonstrating that biological potency inversely correlates with IGFBP binding affinity.